How do I manage breast cancer and osteoporosis at 56?

Question

Hi doctor,

I am a 56-year-old woman currently undergoing treatment for hormone receptor–positive, HER2-negative breast cancer. I had a lumpectomy six months ago and have since been on Letrozole as part of my adjuvant endocrine therapy.

I recently had a DEXA scan that showed a T-score of -2.7 at the lumbar spine and -2.4 at the femoral neck, indicating osteoporosis. My serum calcium is 9.1 mg/dL, vitamin D is 18 ng/mL, and PTH is mildly elevated at 75 pg/mL.

I have been experiencing back pain and increasing fatigue, and I am concerned about the long-term effects of aromatase inhibitors on my bone health.

My oncologist mentioned possibly starting a bisphosphonate or Denosumab, but I am not sure which is safer, given my dental history of extractions and sensitive gums. Should I be worried about osteonecrosis of the jaw with these drugs? Also, how often should bone density be monitored during treatment? I am already taking calcium and vitamin D supplements, but is that enough? Can physical activity or diet meaningfully help in my case?

I am also wondering whether the bone loss increases my fracture risk during cancer treatment, and whether I should see an endocrinologist in addition to my oncologist.

Please help.

Answer 1

Hi,

Welcome to icliniq.com.

I understand your concern.

Aromatase inhibitors such as Letrozole are highly effective at reducing recurrence risk in hormone receptor–positive breast cancer, but they do accelerate bone loss, which explains your osteoporosis findings and the elevated fracture risk.

A T-score of -2.7 at the spine already indicates significant bone fragility, and your low vitamin D level and elevated parathyroid hormone suggest secondary hyperparathyroidism due to vitamin D deficiency, further worsening bone health.

Calcium and vitamin D supplementation are necessary but usually not sufficient in this setting, so additional bone-directed therapy is generally recommended. Both bisphosphonates and Denosumab are effective in strengthening bone, reducing fractures, and may even lower breast cancer recurrence risk in postmenopausal women. However, both carry a small risk of osteonecrosis of the jaw, especially in individuals with a history of dental extractions or ongoing gum problems.

The absolute risk remains low but should be minimized by addressing dental issues and maintaining good oral hygiene before and during treatment. Regular dental checkups are important, and if invasive procedures are needed, they should ideally be completed before starting therapy.

Bone mineral density is typically monitored every one to two years during aromatase inhibitor treatment, but in patients with osteoporosis, yearly scans may be more appropriate to assess response. Physical activity, particularly weight-bearing and resistance exercises, can meaningfully improve bone strength and balance, reducing fracture risk, and a diet rich in calcium and adequate protein further supports bone health.

Given your osteoporosis, biochemical abnormalities, and cancer treatment context, consulting an endocrinologist alongside your oncologist would be very valuable to optimize bone management and ensure coordinated care.

I hope this has helped you.

Please feel free to reach out to me again for further queries.

Thank you.